For Immediate Release
Company Contact:
Marsha Ann Marsh
Building a Strong Data Foundation in the Age of AI
Artificial intelligence (AI) has become a key priority in the boardroom and across management —…
Learn More
SeraCare Life Sciences, Inc
508.244.6400 ext. 6106 203.550.5978
mmarsh@seracare.com
www.seracare.com
Agency Contact:
Shannon Meirzon
Pyxis Communications
shannon@pyxiscommunications.com
www.pyxiscommunications.com
SeraCare Life Sciences and Dr. Jack Wands Spark Advancements in Oncology Diagnostics
Milford, Massachusetts, February 11, 2014 – SeraCare Life Sciences, a provider of high
quality biological materials and reagents that help optimize diagnostic performance, reliability
and repeatability across the IVD lifecycle, today introduced Dr. Jack Wands as the founding
member of the SeraCare Science Advisory Board. This group will bring together thought leaders
in emerging technologies and applications such as NexGen sequencing, clinical oncology and
autoimmune disease to foster collaboration and innovation.
“We are excited to welcome Dr. Wands as the first member of the SeraCare Science Advisory
Board,” said Russell Garlick, Ph.D., Chief Scientific Officer at SeraCare. “Dr. Wands is an
internationally renowned physician scientist and we share a vision for harnessing the power of
precision medicine to advance oncology diagnostics. Each day brings new innovation in our
industry, making it more important than ever that we join forces with the leading research
minds.”
“SeraCare plays a critical role in the discovery of new diagnostic tools and their transformation
into commercial products that improve patients’ lives,” said Dr. Jack Wands, Professor of
Medical Science at Brown Medical School. “It is deeply rewarding to me to join the Science
Advisory Board so I can not only share insights with other researchers, but also see these
concepts brought to life in a way that positively impacts so many people.”
Dr. Wands is the Jeffrey and Kimberly Greenberg-Artemis and Martha Joukowsky Professor in
Gastroenterology, and Professor of Medical Science, Brown Medical School. He founded and
developed the Rhode Island Hospital/Brown University Liver Research Center. His research
efforts involve the role of hepatitis B and C infection in the pathogenesis of hepatocellular
carcinoma at the molecular level. Dr. Wands received his M.D. with High Honors from the
University Of Washington School Of Medicine, was Chief Resident in Medicine at Johns
Hopkins Bayview Medical Center and was a Clinical and Research Fellow at Massachusetts
General Hospital.
About SeraCare Life Sciences, Inc.
SeraCare, a portfolio company of Linden Capital Partners, works with diagnostics researchers,
IVD manufacturers, and clinical laboratories to shape the future of medical diagnostics. Our
innovative portfolio includes ACCURUN® quality controls, research panels, KPL™ antibodies and
immunoassay reagents, SeraCon™ processed plasma, specialty human blood products, and
Complete BioCollections™ materials. SeraCare helps bridge the gap between today’s diagnostic
solutions and tomorrow’s emerging technologies.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged
buyouts in the healthcare and life science industries. Linden’s strategy is based upon three
elements: i) healthcare and life science industry specialization, ii) integrated private equity and
operating expertise, and iii) strategic relationships with large corporations. Linden currently has
investments in middle market platforms in the products, distribution, and services segments of
healthcare. For additional information about Linden, please refer to the firm’s website at
www.lindenllc.com.
# ##
